Email This Article

Excluding Freak Detour, ImClone's Gain is Modest
By Matthew Goldstein
02/13/04 - 01:06 PM EST
The shares inch up on news its cancer drug, Erbitux, won FDA approval.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,464.40 1,110.63 2,176.05 32.79
Oil *
77.05
UP
30.69
UP
4.98
UP
6.87
DOWN
0.38
10 Yr
3.28%
SPDR Gold
116.62
+0.29%
+0.45%
+0.32%
-1.15%
Data delayed 20 minutes

Brokerage Partners